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Introduction
Despite the recent gains in malaria control, the disease remains 
a major public health risk, with 216 million cases and 445,000 
deaths associated with malaria in 20161. Progress in malaria 
control has stalled and may have reversed in some areas2.
RTS,S/AS01E is the most advanced candidate malaria vaccine 
and is based on the circumsporozoite protein (CSP) that targets 
the pre- erythrocytic cycle of Plasmodium falciparum in humans. 
Vaccination with RTS,S/AS01E has been partially efficacious 
against malaria in phases II and III trials in Africa3,4. RTS,S/
AS01E induces pre-erythrocytic immunity. In contrast, naturally 
acquired immunity to malaria is largely dependent on antibodies to 
blood-stage parasites including the merozoite stage. Although 
there are no unambiguous correlates of natural immunity5, anti-
bodies to merozoite antigens have been associated with protec-
tion through multiple mechanisms including the inhibition of 
erythrocyte invasion and replication6, complement-dependent 
mechanisms7, and enhancement of uptake and clearance by 
circulating phagocytes8,9. Antibodies to antigens expressed on 
the surface of infected red blood cells (iRBCs) have also been 
associated with immunity, which could inhibit or reverse seques-
tration of iRBCs, inhibit formation of rosettes, and promote 
opsonization of iRBCs for uptake by phagocytes10–12.
Antibodies to malaria parasites are acquired as a result of 
exposure. As such, interventions like insecticide impregnated 
bed nets and RTS,S/AS01E -vaccination that reduce exposure 
to blood-stage antigen will affect the rate at which antibodies to 
merozoite and other blood-stage antigens are acquired. Previ-
ously, we and others demonstrated that RTS,S/AS01E and RTS,S/
AS02 vaccinations reduced blood stage antibody levels, likely as 
a result of reducing the exposure to blood stage parasites due to 
induction of partial pre-erythrocytic immunity13,14. However, the 
duration of this effect remains unknown. It is important to deter-
mine the duration of this effect as RTS,S/AS01E vaccination 
could delay the development of naturally acquired immunity, 
increasing the possibility of continued susceptibility in older 
children after the waning of the vaccine induced immunity15.
In this study, we aimed to determine the durability of the previ-
ously reported reduction in antibody levels to merozoite antigens 
in children receiving RTS,S/AS01E vaccination, relative to 
Rabies control vaccines13. We analysed plasma samples collected 
from children during a seven-year extended follow up of a phase 
IIb randomized, controlled trial of RTS,S/AS01E among young 
children in Kilifi, Kenya, examining antibodies to 4 differ-
ent merozoite antigens by enzyme-linked immunosorbent assay 
(ELISA). We then analysed the effect of RTS,S/AS01E vaccination 
on the acquisition of these antibodies and tested for poten-




447 healthy Kenyan children aged 5 – 17 months were randomized 
in a 1:1 ratio to receive 3 doses at monthly intervals of either 
RTS,S/AS01E or Rabies vaccine in a phase 2b trial, to evaluate the 
efficacy and safety of RTS,S/AS01E against clinical malaria epi-
sodes by P. falciparum infection. Details have been published else-
where3.
Monitoring for episodes of clinical malaria
The primary end point was a clinical episode of malaria, defined 
as an axillary temperature of >37.5°C, with a P. falciparum 
parasite density of 2500 parasites/microlitre of blood. Active 
surveillance was implemented with weekly home visits, where 
children were screened for fevers associated with P. falciparum 
parasites, both during the trial and the extended follow up 
period. A parallel passive surveillance was implemented by field 
workers residing in the study villages and health care staff in 
local health facilities.
Asymptomatic infections were detected by both microscopy 
and blood-smears during the cross-sectional data and sample 
collecton surveys described below.
Blood samples
Vaccines doses were given at month 1, 2 and 3. Blood samples 
were initially taken (1) before vaccination (in March 2007), (2) 
1 month after dose 3, (3) in March 2008 (i.e., mean, 8 months; 
range, 4–10 months after dose 3), and (4) 12 months after dose 3. 
Subsequently, the study was extended to test the duration of vac-
cine induced immunity, and further blood samples were col-
lected in March (5) 2009, (6) 2010, (7) 2011, (8) 2012, (9) 2013, 
and (10) 2014. Separated plasma was aliquoted and stored at 
80°C until assayed.
Previously, we reported anti-merozoite antibody responses for 
the samples collected from four time points during the first 14 
months of follow up13. In the current study, we extend the analy-
sis to samples collected during the extended study, including 10 
timepoints taken over 7 years; i.e. pre-vaccination (i.e. month 0), 
then at 4, 6.5, 8, 14, 24, 36, 48, 60, 72, and 84 months.
ELISA
Samples were tested by ELISA for the presence of human IgG 
against the following P. falciparum antigens as described else-
where16: MSP142, 3D7 sequence expressed in Escherichia 
coli17; MSP3, FVO sequence, expressed in E. coli18; the receptor-
binding domain II (PfEBA175RII) of EBA175, 3D7 sequence, 
expressed in P. pastoris19; and AMA1, 3D7 sequence expressed 
in E. coli20. In brief, each antigen was coated onto high absorb-
ance plates (Immulon4 HBX) at a con- centration of 0.5 micro-
grams/mL and stored at 4°C overnight. The plates were washed 
3 times in phosphate-buffered saline (PBS) with 0.05% 
Tween 20 (PBS-T) and blocked for 3 h with blocking buffer (1% 
w/v dried skimmed milk powder in PBS-T). After 3 additional 
washes, 100 microlitre of each plasma sample were added to 
duplicate wells at a final dilution of 1/1000 in PBS-T. The next 
day, after 5 washes, 100 microlitre of horse radish peroxidase– 
conjugated antihuman IgG (DAKO) at a dilution of 1:5000 in 
blocking buffer was added to each well, and plates were incubated 
for 3 h. The plates were then developed using H202 as substrate 
and OPD (Sigma) as the colorimetric indicator for 20 min in 
the dark. Plates were read at 492 nm on a Molecular Devices 
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Versa Max ELISA reader. Tests were repeated if duplicate 
optical density (OD) values for an individual plasma sample var-
ied by more than a factor of 1.5. A pool of serum samples from 
an area in Africa where malaria is highly endemic was titrated 
on each plate and acted both as a positive control and provided 
values for a standard curve for converting optical density (OD) 
readings into arbitrary units, minimizing inter-plate and inter-day 
variations. A 3-parameter sigmoid ligand binding model was 
used to least-squares fit a curve to the values of the hyperendemic 
serum sample pool, and this was used to calculate sample antibody 
levelss on each plate.
Statistical analysis
Antibody scores from ELISAs were expressed relative to the OD 
readings obtained from the hyperimmune standard, with a score 
of 1000 scaled to be the maximum reactivity seen at the low-
est dilution used in the hyperimmune standard curve, and then 
log-transformed before analysis. Student’s T-test with compari-
son of means and non-parametric analyses with comparisons of 
medians and rank sum tests were used to compare groups. For 
the prospective association with malaria risk, the antibody lev-
els were split into deciles, and a Poisson regression analysis was 
conducted with the unit of analysis being the period of time after 
each antibody level was estimated, hence including up to 10 
observations per child, using the clustered sandwich estimate 
in Stata 15 (StataCorp LLC). We used the exposure index, as 
previously described21, to estimate exposure to malaria based on 
geographical location.
Results
1735 plasma samples collected from 10 time points: at 0 (i.e. 
pre-vaccination), 4, 6.5, 8, 14, 24 (March 2009; n = 314), 36 
(March 2010; n = 303), 48 (March 2011; n=295), 60 (March 
2012; n=276), (72) (March 2013; n = 269), and 84 (March 2014; 
n=278) months of the third dose of vaccination were tested for anti-
body levels. The antibody levels varied widely, with the majority 
of the children being unresponsive (i.e. lower than the lowest 
value on the straight part of the sigmoid curve based on the dilu-
tion of the hyperimmune standard serum), while the rest had values 
lying within the straight part of the hyperimmune standard 
curve (Figure 1).
Anti-merozoite antigen antibody levels split by RTS,S/
AS01E vaccination
Geometric mean antibody levels for all the 4 merozoite antigens 
increased with age, irrespective of vaccination group, but this 
was more apparent for 3 of the 4 antigens, and less apparent for 
AMA1 (Figure 2). There were indications of seasonal variation 
during the first year of sampling when 4 samples were collected 
per child, as previously described13, but it was not possible to 
assess seasonality once sampling was scaled back to 1 sample 
per child per year, timed to occur in the dry period just before the 
main transmission season. Antibody levels for AMA1, EBA175 
and MSP142 diverged after vaccination, with levels being higher 
among the Rabies control vaccinees than the RTS,S/AS01E vac-
cinees at months 12, 24 and 36, 24 and 36, and 6, 12, 24, 36 
and 84 of the third dose of vaccination for AMA1, EBA175 
and MSP142, respectively (Figure 2). Thus, the divergence was 
temporal for AMA1 and EBA175, as the differences in the median 
antibody levels reduced with time and were similar by 48 months 
of the third dose of vaccination. In contrast, anti-MSP142 anti-
body levels were still higher among the Rabies-control than the 
RTS,S/AS01E vaccinees at 84 months of the third dose (the last 
time point of sampling) with statistical significance (Table 1). 
Similar patterns were seen on non-parametric analyses with 
medians.
Figure 1. Distribution of anti-merozoite antibody levels. Antibody levels were measured by ELISA.
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Figure 2. Comparison of the mean levels of anti-merozoite antigen-specific antibodies between RTS,S/AS01E and Rabies control 
vaccinees. Antibody levels were determined by ELISA and the values log-transformed to achieve normal distributions. Student’s T-test with 
comparison of means and non-parametric analyses with comparisons of medians and rank sum tests were used to compare groups. The 
read blue and red lines indicate the mean levels of RTS,S/AS01E and Rabies control vaccinations, respectively. The shaded regions indicate 
the 95% confidence intervals.
Table 1. Comparisons of the geometric mean antibody levels 
of antibody levels between RTS,S/AS01E and Rabies control 
vaccines at different time points.
Antigen Month RTS,S/AS01E Rabies Control P value
ama1 0 1.61 (1.56-1.66) 1.66 (1.61-1.71) 0.156
ama1 4 1.56 (1.53-1.59) 1.55 (1.53-1.58) 0.705
ama1 8.5 1.59 (1.56-1.63) 1.55 (1.53-1.58) 0.057
ama1 12 1.67 (1.61-1.73) 1.61 (1.56-1.66) 0.116
ama1 24 1.64 (1.6-1.69) 1.58 (1.55-1.62) 0.031
ama1 36 1.68 (1.62-1.73) 1.62 (1.58-1.67) 0.12
ama1 48 1.7 (1.65-1.76) 1.67 (1.62-1.72) 0.311
ama1 60 1.8 (1.73-1.87) 1.78 (1.71-1.84) 0.628
ama1 72 1.85 (1.8-1.9) 1.83 (1.78-1.88) 0.588
ama1 84 1.92 (1.86-1.98) 1.9 (1.85-1.96) 0.605
eba175 0 1.66 (1.6-1.71) 1.71 (1.66-1.76) 0.114
eba175 4 1.61 (1.58-1.63) 1.61 (1.58-1.63) 0.939
eba175 8.5 1.65 (1.62-1.68) 1.62 (1.6-1.65) 0.208
eba175 12 1.75 (1.69-1.81) 1.69 (1.65-1.73) 0.095
eba175 24 1.74 (1.7-1.79) 1.68 (1.65-1.71) 0.016
eba175 36 1.79 (1.74-1.84) 1.71 (1.68-1.75) 0.008
eba175 48 1.76 (1.7-1.82) 1.68 (1.65-1.72) 0.023
eba175 60 1.88 (1.82-1.95) 1.78 (1.73-1.83) 0.011
eba175 72 1.98 (1.93-2.03) 1.92 (1.88-1.96) 0.068
Antigen Month RTS,S/AS01E Rabies Control P value
eba175 84 1.97 (1.92-2.02) 1.94 (1.9-1.98) 0.435
msp142 0 1.75 (1.67-1.84) 1.81 (1.72-1.9) 0.36
msp142 4 1.72 (1.65-1.79) 1.7 (1.64-1.76) 0.687
msp142 8.5 1.81 (1.74-1.88) 1.69 (1.63-1.74) 0.006
msp142 12 1.99 (1.87-2.11) 1.86 (1.76-1.95) 0.083
msp142 24 2.08 (1.99-2.16) 1.93 (1.85-2) 0.009
msp142 36 2.12 (2.04-2.2) 1.99 (1.92-2.07) 0.016
msp142 48 2.07 (1.99-2.14) 2 (1.93-2.07) 0.186
msp142 60 2.15 (2.08-2.22) 2.08 (2.01-2.14) 0.116
msp142 72 2.34 (2.29-2.4) 2.28 (2.23-2.32) 0.069
msp142 84 2.32 (2.27-2.38) 2.25 (2.2-2.29) 0.019
msp3 0 1.73 (1.67-1.78) 1.7 (1.65-1.75) 0.412
msp3 4 1.71 (1.67-1.75) 1.66 (1.62-1.7) 0.084
msp3 8.5 1.59 (1.56-1.62) 1.58 (1.56-1.6) 0.563
msp3 12 1.7 (1.63-1.76) 1.64 (1.59-1.69) 0.134
msp3 24 1.7 (1.66-1.74) 1.66 (1.63-1.69) 0.191
msp3 36 1.75 (1.7-1.8) 1.7 (1.66-1.74) 0.126
msp3 48 1.75 (1.71-1.8) 1.73 (1.69-1.77) 0.476
msp3 60 1.82 (1.76-1.88) 1.75 (1.7-1.79) 0.062
msp3 72 2.18 (2.13-2.22) 2.16 (2.13-2.19) 0.444
msp3 84 2.2 (2.16-2.24) 2.17 (2.14-2.21) 0.396
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unknown. Here, we investigated the longevity of the reduction of 
antibody levels to four blood stage antigens after an extended follow 
up of the vaccines and controls for up to 7 years post-vaccination. 
We found that immunization with RTS,S/AS01E and the asso-
ciated clinical protection resulted in the reduction of antibody 
response to MSP142, AMA1 and EBA175 antibody levels but not 
for MSP3. While the antibody levels for AMA1 and EBA175 
among RTS,S/AS01E vaccinees were below those measured in 
the Rabies control vaccinees during the first 48 months of moni-
toring, antibodies to MSP124 remained lower in the RTS,S/AS01E 
vaccinees than in the controls throughout the study period. 
This latter, persistent difference was statistically significant except 
at the very last timepoint, when statistical significance was only 
marginal, considering that there are multiple comparisons by 
timepoint and by adjuvant (p=0.019).
In this study, antibody levels to four specific merozoite antigens 
were not associated with clinical protection. Rather anti-mero-
zoite antibody levels were positively associated with the risk of 
clinical malaria for the group as a whole. The most likely 
explanation for this is that antibody responses are markers of 
exposure, and therefore represent ongoing risk of future expo-
sure to malaria, and this interpretation is supported by the fact 
that the positive association was reduced after controlling for the 
exposure index. It is possible that higher antibody titers might 
have been protective (i.e. those above a protective threshold22). 
In the presence of asymptomatic infection, anti-EBA175 anti-
bodies at all the deciles were higher than the lowest (i.e. non- 
reactive) decile, and some of the higher deciles for AMA1 and 
Figure 3. Prospective association of antibodies with immunity to malaria. Antibody levels were split into deciles and tested for association 
with the numbers of malaria episodes in the ensuing malaria transmission period, but before the next sampling time point. Poisson regression 
analysis was conducted with the unit of analysis being the period of time after each antibody level was estimated, hence including up to 7 
observations per child, using the clustered sandwich estimate. The analysis adjusted for age, exposure index, vaccine arm, and bed net 
usage. The red and blue dots indicate unadjusted and adjusted analyses. The green and orange dots indicate analysis for parasite negative 
and positive samples.
Antibody levels and subsequent risk of clinical malaria
Antibody levels were split into deciles, which were then tested 
for prospective associations with protection from malaria in the 
transmission period after each, but before, the next sampling 
time-point. Pre-existing antibody levels for the 4 different 
merozoite proteins were not associated with clinical immunity 
(Figure 3). Instead, the incident rate ratio for clinical malaria 
increased with rising antibody levels. This relationship was 
most apparent at higher antibody levels (>5th decile) for AMA1 
and EBA175 (irrespective of vaccine arm). However, the incident 
rate ratios for the effect of antibodies on clinical malaria reduced 
after controlling for heterogeneity in malaria exposure using 
an exposure index, suggesting that these anti-merozoite antibodies 
are markers of exposure, rather than immunity.
Furthermore, when all the data were stratified by asympto-
matic-parasite positivity at sampling by microscopy, the highest 
levels for AMA1 and MSP3, and all the of levels for EBA175 
above the non-reactive group, were associated with reduced rate 
ratios for clinical malaria, among the children with asymptomatic 
parasitaemia at the time of sampling. Associations between 
higher antibody levels and increased incident rate ratios were 
maintained among the children without asymptomatic parasitaemia 
(Figure 3).
Discussion
We and others reported previously that RTS,S/AS01E vaccina-
tion resulted in a reduction in antibody levels to blood stage 
malaria antigens13,14. However, the duration of this effect is 
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MSP3 antibodies were associated with protection from clinical 
malaria (irrespective of the vaccine arm). This finding is con-
sistent with several previous studies where analyses of single 
antigen-specific antibody responses within whole populations 
demonstrated no protective effect of antimalarial antibodies, but 
the same antibodies were associated with clinical immunity when 
parasite-positive individuals were analysed separately22,23. Our 
analysis involves only four antigens and there is evidence that the 
breadth of antibody positivity is also important for protection24,25.
An RTS,S/AS01E induced reduction in blood stage immunity will 
have implications for the outcomes of vaccination if the vaccine 
is deployed for routine use among African children. If vaccina-
tion resulted in delayed development of natural immunity, then 
some of the gains of the vaccination may be offset by delayed 
susceptibility as the vaccine induced immunity wears off. Stud-
ies done to date on Phase II trials have suggested this possibil-
ity with a three-dose vaccine regimen15, although the effect may 
be countered by a fourth dose26. We show here that antibodies 
to blood stage immunity are reduced after vaccination with RTS,S/
AS01E, which is consistent with induction of pre-erythrocytic 
immunity leading to a reduced incidence of blood-stage parasi-
taemia. However, antibodies induced by natural exposure to the 
four blood stage antigens tested were not consistently associated 
with immunity to malaria and there is no widely accepted or con-
sistent immunological marker for immunity to malaria. It will be 
important to combine RTS,S/AS01E with other malaria control 
measures like insecticide treated nets for protecting individu-
als from malaria, and further clinical evaluations of the four-dose 




Havard Dataverse: Replication Data for: Effect of rtss vaccina-
tion on blood stage immunity data, https://doi.org/10.7910/DVN/
KH9ESP27.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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